KCNH2 and familial long QT syndrome: This has prompted the development of a KCNH2 SupRep construct,designed as a potential treatment for LQT 2 patients, with initial safety andefficacy trials currently underway in rabbit models with KCNH2-mediated LQTs[87, 88].